Patrys Ltd has released a press release.
Full size deoxymab PAT-DX3 crosses the blood brain barrier
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Patrys
- Response to ASX Query
- Patrys Limited Announces Publication of PAT-DX1 Preclinical Data in JCI - Insight
- Paper highlights PAT-DX1 as potential brain cancer treatment
- Patrys receives R&D Tax Incentive refund
- Appendix 4C - Quarterly - 31 March 2021
Later from Patrys
- PAT-DX1 Improves Survival in Model of Pancreatic Cancer
- Appendix 4C - Quarterly - 30 June 2021
- Market Update - PAT-DX1 Clinical Trial Preparation
- Appendix 4E and 2021 Annual Report
- PAT-DX3 proof of concept as potential ADC targeting antibody
Follow Patrys into a list and get an email when it puts out news.
Follow Patrys